European Journal of Biomedical and Pharmaceutical Sciences

SERUM VISFATIN AND LIPID PROFILES IN PATIENTS WITH TYPE II DIABETES IN COMPARISON WITH HEALTHY CONTROLS IN KHARTOUM STATE-SUDAN

Bashir Mohamed Bashir Hamza*, Fatimaalzahra Ahmed Mohamed Osman, Afrah Gasmallh Babeker, Arwa Mohammed Saeed, Tasabeeh Elser, NassrEldinM.A.Shrif

ABSTRACT

Visfatin is an adipocytokine which is secreted largely by visceral adipose tissue. It acts synergistically with insulin in increasing glucose cellular uptake, it also has an insulin-like effects through direct connection and activation of insulin receptors without any change or competition with the insulin .The aim of this study was to explore the relation of serum visfatin and lipid profile in T2DM in the context of the role of glycemic control. A total of 45 T2DM Sudanese patients and 45 healthy control subjects, matched for age, body mass index (BMI) and sex ratio, were enrolled. Analytical, hospital base case control study was conducted during the period from January to May 2015. Serum levels of visfatin, total Cholesterol, Triglyceride, HDL cholesterol, LDL cholesterol, and blood HbA1c were estimated.Serum visfatin levels was higher in T2DM patients, compared to control (3.3± 2.2), (2.0 ± 0.5) respectively (P<0.001). There was no significant difference in the mean of serum levels of visfatin in good glycemic controlled patients (3 ± 1.7in comparison with non-glycemic controlled groups (3.6 ± 2.6) (P=0.30). There was no significant difference in the mean of serum levels of visfatin between good glycemic controlled patients and non-glycemic controlled groups (3 ± 1.7) (3.6 ± 2.6) respectively (P=0.30). There was significant correlation between serum visfatin with Triglyceride, HDL cholesterol, and insignificant correlation between serum visfatin with Total cholesterol and LDL cholesterol.

Keywords: T2DM, Visfatin, lipid profiles, Sudanese.